{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:10:06Z","timestamp":1745939406553,"version":"3.40.4"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jad-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.jad.2012.11.054","type":"journal-article","created":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T12:10:40Z","timestamp":1356091840000},"page":"84-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine"],"prefix":"10.1016","volume":"148","author":[{"given":"David E.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc De","family":"Hert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zia","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Fyans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Eudicone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina V.","family":"Marler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit X.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2012.11.054_bib1","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jad.2012.11.054_bib2","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/JGP.0b013e3181b047e3","article-title":"Obesity and metabolic syndrome increase the risk of incident depression in older men: the health in men study","volume":"17","author":"Almeida","year":"2009","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1176\/ajp.2006.163.7.1199","article-title":"Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder","volume":"163","author":"Bowden","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/archpsyc.57.5.481","article-title":"A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group","volume":"57","author":"Bowden","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4088\/JCP.09m05482yel","article-title":"Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial","volume":"71","author":"Bowden","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jad.2012.11.054_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4088\/JCP.v64n0906","article-title":"A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder","volume":"64","author":"Calabrese","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib8","article-title":"The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders","author":"Calkin","year":"2012","journal-title":"Annals of Medicine"},{"key":"10.1016\/j.jad.2012.11.054_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.biopsych.2004.02.009","article-title":"Cytokines and psychopathology: lessons from interferon-alpha","volume":"56","author":"Capuron","year":"2004","journal-title":"Biological Psychiatry"},{"issue":"64","key":"10.1016\/j.jad.2012.11.054_bib10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.biopsych.2008.05.019","article-title":"Depressive symptoms and metabolic syndrome: is inflammation the underlying link?","author":"Capuron","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1399-5618.2011.00974.x","article-title":"Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)","volume":"14","author":"Carlson","year":"2012","journal-title":"Bipolar Disorder"},{"key":"10.1016\/j.jad.2012.11.054_bib12","first-page":"A42","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Preventing Chronic Disease"},{"key":"10.1016\/j.jad.2012.11.054_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/j.2051-5545.2011.tb00036.x","article-title":"Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level","volume":"10","author":"De Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib14","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"European Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.jad.2012.11.054_bib16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2165\/00023210-200822080-00004","article-title":"Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden","volume":"22","author":"Fagiolini","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2012.11.054_bib17","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jad.2012.11.054_bib18","unstructured":"Health, N.I.O. 2004. ATP III Update 2004: Implications of Recent Clinical Trials for the ATP III Guidelines. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), National Institutes of Health: National Heart, Lung, and Blood Institute."},{"key":"10.1016\/j.jad.2012.11.054_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor","volume":"441","author":"Jordan","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.jad.2012.11.054_bib20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania","volume":"160","author":"Keck","year":"2003","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3928\/00485713-20120507-05","article-title":"Cardiometabolic health in bipolar disorder","volume":"42","author":"Kemp","year":"2012","journal-title":"Psychiatric Annals"},{"key":"10.1016\/j.jad.2012.11.054_bib22","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.4088\/JCP.09m05159gre","article-title":"Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder: a post hoc analysis of a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Kemp","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib23","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1399-5618.2010.00823.x","article-title":"Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine\/metabolic system and treatment outcome","volume":"12","author":"Kemp","year":"2010","journal-title":"Bipolar Disorder"},{"key":"10.1016\/j.jad.2012.11.054_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.euroneuro.2011.06.005","article-title":"Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: long-term changes in weight and metabolic profiles","volume":"22","author":"Kemp","year":"2012","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2012.11.054_bib25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jad.2012.11.054_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4088\/JCP.v69n0202","article-title":"Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study","volume":"69","author":"Koponen","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib27","doi-asserted-by":"crossref","first-page":"e24597","DOI":"10.1371\/journal.pone.0024597","article-title":"Chronic somatic comorbidity and excess mortality due to natural causes in persons with schizophrenia or bipolar affective disorder","volume":"6","author":"Laursen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jad.2012.11.054_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2337\/dc06-1414","article-title":"The National Cholesterol Education Program\u2014Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes","volume":"30","author":"Lorenzo","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jad.2012.11.054_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-5618.2011.00898.x","article-title":"Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study","volume":"13","author":"Marcus","year":"2011","journal-title":"Bipolar Disorder"},{"key":"10.1016\/j.jad.2012.11.054_bib30","first-page":"69","article-title":"The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders","volume":"24","author":"McIntyre","year":"2012","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jad.2010.04.012","article-title":"Bipolar disorder and metabolic syndrome: an international perspective","volume":"126","author":"McIntyre","year":"2010","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.jad.2012.11.054_bib32","article-title":"A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder","volume":"13","author":"McIntyre","year":"2011","journal-title":"Primary Care Companion for CNS Disorders"},{"key":"10.1016\/j.jad.2012.11.054_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11892-009-0010-0","article-title":"Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap","volume":"9","author":"McIntyre","year":"2009","journal-title":"Current Diabetes Reports"},{"key":"10.1016\/j.jad.2012.11.054_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/14740338.5.1.157","article-title":"The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms","volume":"5","author":"McIntyre","year":"2006","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.jad.2012.11.054_bib35","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJM200103293441303","article-title":"Paroxetine for the prevention of depression induced by high-dose interferon alfa","volume":"344","author":"Musselman","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jad.2012.11.054_bib36","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00125-011-2268-4","article-title":"Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults","volume":"55","author":"Pan","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.jad.2012.11.054_bib37","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1053\/meta.2002.36301","article-title":"The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence?","volume":"51","author":"Raikkonen","year":"2002","journal-title":"Metabolism"},{"key":"10.1016\/j.jad.2012.11.054_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2008.02.096","article-title":"Comparison of waist circumference versus body mass index in diagnosing metabolic syndrome and identifying apparently healthy subjects at increased risk of cardiovascular disease","volume":"102","author":"Ryan","year":"2008","journal-title":"American Journal of Cardiology"},{"key":"10.1016\/j.jad.2012.11.054_bib39","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2012.11.054_bib40","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.4088\/JCP.08r04392","article-title":"Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review","volume":"70","author":"Simon","year":"2009","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/CVM-1-1-025","article-title":"Debate: subgroup analyses in clinical trials: fun to look at\u2014but don't believe them!","volume":"1","author":"Sleight","year":"2000","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"key":"10.1016\/j.jad.2012.11.054_bib42","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4088\/JCP.v68n0308","article-title":"Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review","volume":"68","author":"Spurling","year":"2007","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-006-0621-y","article-title":"Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies","volume":"190","author":"Stark","year":"2007","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jad.2012.11.054_bib44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127)","volume":"166","author":"Suppes","year":"2009","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0b013e31823f872f","article-title":"Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension","volume":"32","author":"Szegedi","year":"2012","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/j.jad.2012.11.054_bib46","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.4088\/JCP.v69n1113","article-title":"Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study","volume":"69","author":"Tohen","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01204.x","article-title":"Weight gain in bipolar disorder: pharmacological treatment as a contributing factor","volume":"118","author":"Torrent","year":"2008","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1016\/j.jad.2012.11.054_bib48","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-5618.2007.00520.x","article-title":"Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder","volume":"10","author":"van Winkel","year":"2008","journal-title":"Bipolar Disorder"},{"key":"10.1016\/j.jad.2012.11.054_bib49","doi-asserted-by":"crossref","unstructured":"Vancampfort, D., Vansteelandt, K., Correll, C.U., Mitchell, A., De Hert, A., Sienaert, P., Probst, M. & De Hert, M. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. American Journal of Psychiatry, in press.","DOI":"10.1176\/appi.ajp.2012.12050620"},{"key":"10.1016\/j.jad.2012.11.054_bib50","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1185\/03007991003779380","article-title":"Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium\/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study","volume":"26","author":"Vieta","year":"2010","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.jad.2012.11.054_bib51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.jad.2012.11.054_bib52","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/appi.ajp.2008.07101560","article-title":"Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate\/lithium monotherapy: a placebo-controlled study","volume":"165","author":"Vieta","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib53","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1176\/appi.ajp.2011.11060958","article-title":"Switching antipsychotic medications: not enough, too often, or just right?","volume":"168","author":"Weiden","year":"2011","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.jad.2012.11.054_bib54","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.4088\/JCP.08m04767blu","article-title":"Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome","volume":"71","author":"Zeugmann","year":"2010","journal-title":"Journal of Clinical Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271200821X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503271200821X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T14:52:15Z","timestamp":1745938335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503271200821X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S016503271200821X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2012.11.054","relation":{},"ISSN":["0165-0327"],"issn-type":[{"type":"print","value":"0165-0327"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2012.11.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}